Dose-dependence of the nifedipine-digoxin interaction? 1986

W Kirch, and H J Hutt, and P Dylewicz, and K J Gräf, and E E Ohnhaus

The dose-dependence of the nifedipine-digoxin interaction was investigated in seven healthy subjects. After an adequate loading dose of digoxin for 2 weeks, 0.25 mg digoxin b.i.d. was given by mouth by itself. Afterwards, 0.25 mg digoxin was given twice a day for three 1-week periods in combination with capsules of nifedipine, 5, 10, or 20 mg, respectively, given on a thrice-daily basis. The study ended with a digoxin monotherapy phase lasting 7 days. All three doses of nifedipine significantly increased digoxin plasma concentrations and AUC compared with digoxin monotherapy. Thus, for example, the AUC was 10.16 +/- 0.88 ng/ml . hr (mean +/- SE) when digoxin was given alone and 12.33 +/- 1.59 ng/ml . hr with concurrent nifedipine, 5 mg t.i.d. (P less than 0.05). Nifedipine causes a slight but significant increase (15%) in digoxin plasma concentrations and AUC. This effect did not depend on the nifedipine dose given in the range studied.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D009543 Nifedipine A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure. Adalat,BAY-a-1040,Bay-1040,Cordipin,Cordipine,Corinfar,Fenigidin,Korinfar,Nifangin,Nifedipine Monohydrochloride,Nifedipine-GTIS,Procardia,Procardia XL,Vascard,BAY a 1040,BAYa1040,Bay 1040,Bay1040,Monohydrochloride, Nifedipine,Nifedipine GTIS
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D004077 Digoxin A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digacin,Digitek,Digoregen,Digoxina Boehringer,Digoxine Nativelle,Dilanacin,Hemigoxine Nativelle,Lanacordin,Lanicor,Lanoxicaps,Lanoxin,Lanoxin-PG,Lenoxin,Mapluxin,Boehringer, Digoxina,Lanoxin PG,Nativelle, Digoxine,Nativelle, Hemigoxine
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D006321 Heart The hollow, muscular organ that maintains the circulation of the blood. Hearts
D006339 Heart Rate The number of times the HEART VENTRICLES contract per unit of time, usually per minute. Cardiac Rate,Chronotropism, Cardiac,Heart Rate Control,Heartbeat,Pulse Rate,Cardiac Chronotropy,Cardiac Chronotropism,Cardiac Rates,Chronotropy, Cardiac,Control, Heart Rate,Heart Rates,Heartbeats,Pulse Rates,Rate Control, Heart,Rate, Cardiac,Rate, Heart,Rate, Pulse
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

W Kirch, and H J Hutt, and P Dylewicz, and K J Gräf, and E E Ohnhaus
December 1986, Drug intelligence & clinical pharmacy,
W Kirch, and H J Hutt, and P Dylewicz, and K J Gräf, and E E Ohnhaus
April 1986, Danish medical bulletin,
W Kirch, and H J Hutt, and P Dylewicz, and K J Gräf, and E E Ohnhaus
January 1995, East African medical journal,
W Kirch, and H J Hutt, and P Dylewicz, and K J Gräf, and E E Ohnhaus
October 1995, East African medical journal,
W Kirch, and H J Hutt, and P Dylewicz, and K J Gräf, and E E Ohnhaus
January 1987, Kardiologia polska,
W Kirch, and H J Hutt, and P Dylewicz, and K J Gräf, and E E Ohnhaus
May 1985, The American journal of cardiology,
W Kirch, and H J Hutt, and P Dylewicz, and K J Gräf, and E E Ohnhaus
April 1981, Lancet (London, England),
W Kirch, and H J Hutt, and P Dylewicz, and K J Gräf, and E E Ohnhaus
December 1984, British journal of clinical pharmacology,
W Kirch, and H J Hutt, and P Dylewicz, and K J Gräf, and E E Ohnhaus
January 1985, Therapeutic drug monitoring,
W Kirch, and H J Hutt, and P Dylewicz, and K J Gräf, and E E Ohnhaus
August 1987, Journal of cardiovascular pharmacology,
Copied contents to your clipboard!